Monitoring the Response of Combination Ursodiol and Seladelpar Treatment

Inclusion Criteria: * Patients must have a confirmed diagnosis PBC as per established diagnostic criteria. * Adults aged 18 years and older. * Patients undergoing treatment with ursodiol (ursodeoxycholic acid) for PBC or who demonstrate intolerance to ursodiol due to side effects and persistent ALP \> normal. * Patients undergoing treatment with seladelpar for PBC. * Patients must be willing and able to provide written informed consent for participation in the study. Exclusion Criteria: * Patients that do not meet inclusion criteria. * Patients with other chronic liver diseases, such as hepatitis B, hepatitis C, non-alcoholic steatohepatitis (NASH), alcoholic liver disease, or other autoimmune liver diseases. * Patients who have undergone a liver transplant. * Presence of cirrhosis or hepatic decompensation at the time of study enrollment. * Patients with significant comorbid conditions that may interfere with the study outcomes, such as severe cardiovascular, renal, or pulmonary diseases. * Pregnant or breastfeeding women, due to potential risks to the fetus or infant. * Inability or unwillingness to comply with the study protocol, including scheduled visits, tests, and procedures.